NEUROCRINE BIOSCIENCES INC
For the period ended Mar 31, 2024. Filed May 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 1, 2024
NBIX$168.86+2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| (in millions, except share data) | March 31,2024 | December 31,2023 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $396.3 | $251.1 |
| Debt securities available-for-sale | 814.3 | 780.5 |
| Accounts receivable | 450.7 | 439.3 |
| Inventory | 37.2 | 38.3 |
| Other current assets | 100.5 | 97.8 |
| Total current assets | 1,799.0 | 1,607.0 |
| Deferred tax assets | 378.2 | 362.6 |
| Debt securities available-for-sale | 700.4 | 687.5 |
| Right-of-use assets | 270.8 | 276.5 |
| Equity security investments | 163.5 | 161.9 |
| Property and equipment, net | 75.3 | 70.8 |
| Intangible assets, net | 34.3 | 35.5 |
| Other noncurrent assets | 50.9 | 49.6 |
| Total assets | $3,472.4 | $3,251.4 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $417.2 | $448.8 |
| Convertible senior notes, at carrying value ($170.4 face value as of March 31, 2024 and December 31, 2023) | 122.8 | 170.1 |
| Convertible senior notes embedded derivative liability | 136.2 | — |
| Other current liabilities | 36.7 | 35.9 |
| Total current liabilities | 712.9 | 654.8 |
| Noncurrent operating lease liabilities | 252.9 | 258.3 |
| Other noncurrent liabilities | 120.5 | 106.3 |
| Total liabilities | 1,086.3 | 1,019.4 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 220.0 shares authorized; 100.6 and 98.7 shares issued and outstanding, respectively | 0.1 | 0.1 |
| Additional paid-in capital | 2,496.4 | 2,382.0 |
| Accumulated other comprehensive income | 3.3 | 7.0 |
| Accumulated deficit | (113.7) | (157.1) |
| Total stockholders’ equity | 2,386.1 | 2,232.0 |
| Total liabilities and stockholders’ equity | $3,472.4 | $3,251.4 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.